SCHEMBL16178606

SCHEMBL16178606

CC(C)CCN1c2nc(Cl)ncc2N(c2ccccc2)C(=O)C1(C)C

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ELANE P08246 3/20 0.35
MARK3 P27448 1/20 0.34
PIN1 Q13526 1/20 0.34
CCKBR P32239 4/20 0.34
XIAP P98170 4/20 0.33
BIRC2 Q13490 4/20 0.33
MAPT P10636 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
OPRK1 P41145 1/20 0.33
OPRL1 P41146 1/20 0.33
CDK4 P11802 1/20 0.32
CCND1 P24385 1/20 0.32
CCND2 P30279 1/20 0.32
CCND3 P30281 1/20 0.32
ALDH1A1 P00352 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
GRM2 Q14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16178700 0.77 RPS6KA3 (0.47) CCKBRMAPTSMN1; SMN2
SCHEMBL16178626 0.75 PLK1 (0.42) MARK3CDK4CCND1CCND2CCND3
SCHEMBL16178694 0.71 RPS6KA3 (0.35) ALDH1A1
SCHEMBL2028357 0.68 PLK2 (0.51) SMN1; SMN2
SCHEMBL4106908 0.68 SMN1; SMN2 (0.40) MARK3PIN1MAPTALDH1A1SMN1; SMN2
SCHEMBL14952195 0.67 ELANE (0.38) ELANECCKBROPRM1OPRD1OPRK1
SCHEMBL4107807 0.67 MAPT (0.36) ELANEMARK3PIN1MAPTOPRM1
SCHEMBL1675720 0.66 MAPT (0.40) MARK3PIN1MAPTSMN1; SMN2
SCHEMBL21492468 0.66 MARK3 (0.33) MARK3
SCHEMBL14952202 0.65 PIN1 (0.39) PIN1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 US disclosed
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 US disclosed
US-9351974-B2 Substituted pteridinones for the treatment of cancer OSI Pharmaceuticals, LLC (US) 2016-05-31 US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 US disclosed
US-20140315911-A1 DIHYDROPTERIDINONES OSI Pharmaceuticals, LLC 2014-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315911-A1 DIHYDROPTERIDINONES DHPS, DHODH, HYPK ELANE 3971/4885MARK3 4209/4885PIN1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.